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1 
2 
Highlights 3 
 Antimicrobial agent prescription was monitored in a large UK population of cats and dogs over a 4 
2 year period (2014-2016). 5 
 Systemic antimicrobial agents were prescribed more frequently to cats; topical prescription was 6 
more frequent in dogs. 7 
 A temporal reduction (2014-2016) in antimicrobial agent prescription was observed in both cats 8 
and dogs in this population. 9 
 Premises which prescribed antimicrobial agents commonly to cats generally also prescribed 10 
commonly to dogs. 11 
 The most frequently prescribed antibiotics were cefovecin in cats and clavulanic acid potentiated 12 
amoxicillin in dogs. 13 
Abstract 14 
Antimicrobial resistance is an increasingly important global health threat and the use of 15 
antimicrobial agents is a key risk factor in its development. This study describes antimicrobial 16 
agent prescription (AAP) patterns over a 2 year period using electronic health records (EHRs) 17 
from booked consultations in a network of 457 sentinel veterinary premises in the United 18 
Kingdom. A semi-automated classification methodology was used to map practitioner defined 19 
product codes in 918,333 EHRs from 413,870 dogs and 352,730 EHRs from 200,541 cats, 20 
including 289,789 AAPs. AAP as a proportion of total booked consultations was more frequent 21 
in dogs (18.8%, 95% confidence interval, CI, 18.2-19.4) than cats (17.5%, 95% CI 16.9-18.1). 22 
Prescription of topical antimicrobial agents was more frequent in dogs (7.4%, 95% CI 7.2-7.7) 23 
than cats (3.2%, 95% CI 3.1-3.3), whilst prescription of systemic antimicrobial agents was more 24 
frequent in cats (14.8%, 95% CI 14.2-15.4) than dogs (12.2%, 95% CI 11.7-12.7). A decreasing 25 
temporal pattern was identified for prescription of systemic antimicrobial agents in dogs and 26 
cats. Premises which prescribed antimicrobial agents frequently for dogs also prescribed 27 
frequently for cats. AAP was most frequent during pruritus consultations in dogs and trauma 28 
consultations in cats. Clavulanic acid potentiated amoxicillin was the most frequently 29 
prescribed antimicrobial agent in dogs (28.6% of prescriptions, 95% CI 27.4-29.8), whereas 30 
cefovecin, a third generation cephalosporin, was the most frequently prescribed antimicrobial 31 
 agent in cats (36.2%, 95% CI 33.9-38.5). This study demonstrated patterns in AAP over time 32 
and for different conditions in a population of companion animals in the United Kingdom. 33 
Keywords: Canine; Feline; Antimicrobial resistance; Antibiotic prescribing practices; Surveillance  34 
 Introduction 35 
Antimicrobial resistance (AMR) is widely recognised as an increasingly important 36 
global health threat.1,2,3,4 Evidence of transmission of bacterial resistance amongst human 37 
beings, livestock (Cuny et al., 2015) and companion animals1 (Zhang, 2016) demonstrates the 38 
necessity of a ‘one health’ approach to preserve treatment efficacy.2 Although use of 39 
antimicrobial agents selects for and promotes transfer of resistance (Rantala et al., 2004; 40 
Magalhaes et al., 2010; Cantón and Bryan, 2012), data on antimicrobial agent prescription 41 
(AAP) to date are limited in animals. 42 
Antimicrobial agents are frequently prescribed in dogs and cats (Mateus et al., 2011; 43 
Radford et al., 2011; Buckland et al. 2016), and there is evidence of development of resistance 44 
in response to treatment1 (Trott et al., 2004), and transmission of antimicrobial resistant isolates 45 
between human beings and pets (Johnson et al., 2008a, b; Zhang et al., 2016). Specific guidance 46 
for practice level prescription policies have been published5,6 (Beco et al., 2013a, b); however, 47 
there is a need to understand how these are being applied in practice. 48 
Data on human AAP in the United Kingdom (UK) are freely available, in part because 49 
of a national health system.7 For animals, the Veterinary Medicines Directorate (VMD) is 50 
constructing a central body collating data on AAP for the UK; however data currently available 51 
cannot identify antimicrobial agents administered under the cascade prescribing system, which 52 
species they have been prescribed to, practice level prescription variability or why the 53 
                                                          
1 See: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500181642.pdf 
(accessed 15 July 2016). 
2 See: https://www.gov.uk/government/publications/uk-one-health-report-antibiotics-use-in-humans-and-animals 
(accessed 15 July 2016). 
3 See: http://amr-review.org/home (accessed 15 July 2016). 
4 See: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf (accessed 15 July 2016). 
5 See: http://www.bsava.com/Resources/PROTECT.aspx (accessed 4 October 2016). 
6 See: http://www.fecava.org/content/guidelines-policies (accessed 15 July 2016). 
7 See: http://fingertips.phe.org.uk (accessed 15 July 2016). 
 antimicrobial agents were prescribed.8 Advances in veterinary health informatics provides 54 
opportunities to fill this gap, particularly for companion animals where Electronic Health 55 
Records (EHR) are most developed and accessible (O’Neill et al., 2014a). 56 
Early studies of companion animal AAP in the UK were limited in size, but have 57 
consistently pointed to frequent use of β-lactams (Mateus et al., 2011; Radford et al., 2011). 58 
More recently, using a much larger data set, 25% of dogs and 21% of cats seen at veterinary 59 
practices received at least one AAP over a 2 year period (2012-2014), the most frequent being 60 
penicillins and cephalosporins (Buckland et al., 2016). Whilst such ‘big data’ studies have 61 
started to report on AAP, this study aims to describe a near real-time, on-going, AAP 62 
surveillance system from a diverse range of veterinary premises (n = 457) that also consider 63 
AAP in a broad range of practitioner defined clinical presentations. 64 
Materials and methods 65 
Data collection 66 
The Small Animal Veterinary Surveillance Network (SAVSNET) collected EHRs in 67 
near real-time from booked consultations in volunteer UK veterinary practices (1 April 2014-68 
31 March 2016). A full description of the data collection protocol has been described by 69 
Sánchez-Vizcaíno et al. (2015). A practice (n = 216) was defined as a single business, whereas 70 
premise(s) (n = 457) included all branches that form a practice (see Appendix: Supplementary 71 
Figure 1). Before submitting each consultation to SAVSNET, the practitioner selected one of 72 
10 main presenting complaints (MPCs), consisting of a pre-determined list grouped into 73 
healthy, unhealthy and post-operative categories (see Appendix: Supplementary Table 1). The 74 
EHR further included product codes as text strings defined by individual practices. 75 
Antimicrobial agent identification 76 
                                                          
8 See: https://www.gov.uk/government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-
2014 (accessed 15 July 2016). 
 The product codes of the EHR were utilised to identify AAP. A set of 52,267 codes 77 
(extracted 26 August 2015) were manually categorised. Pharmaceutical products were defined 78 
with reference to the VMD’s Product Information Database for veterinary authorised products, 79 
and the electronic Medicines Compendium (Datapharm Communications) for human 80 
authorised products. An identifying string was ascribed to each antimicrobial agent product and 81 
was used to identify the product code. This process was reiterated until all pharmaceutical and 82 
non-pharmaceutical product codes were classified to further validate antimicrobial agent 83 
identification. When applied to the complete list of 95,709 codes (extracted 31 March 2016), 84 
416 antimicrobial agent identifying strings were utilised. 85 
Where possible, product codes for antimicrobial agents were further characterised to 86 
specific species authorisation and administration by systemic (oral or injectable) or topical 87 
(topical, aural or ocular) routes. Whilst not all products were authorised for human use at the 88 
time of the study, we considered all fluoroquinolones, macrolides and third generation 89 
cephalosporins as highest priority critically important antimicrobial agents (HPCIA), as defined 90 
by the World Health Organization (WHO).9 91 
Statistical analysis 92 
Consultation and prescription-level proportions and confidence intervals were 93 
calculated to adjust for clustering (bootstrap method, n = 5000 samples) within premises and at 94 
animal level within practices.10 Pearson correlations (t test to reject null hypothesis) were 95 
performed to explore prescription frequency for dog and cat total, systemic and topical AAP as 96 
a proportion of total submitted consultations for each premises. Paired t tests with Bonferroni 97 
corrections were used for a matched pairs premises level sample to investigate total, systemic 98 
and topical AAP as a proportion of total submitted consultations for each MPC. 99 
                                                          
9 See: http://www.who.int/foodsafety/publications/antimicrobials-fourth/en/ (accessed 13 February 2017). 
10 See: http://cran.r-project.org/package = aod (accessed 11 October 2016). 
 A mixed effects binomial regression model, incorporating practice and premise as 100 
random effects, was utilised to examine quarterly variation in total, systemic and topical canine 101 
and feline AAP as a proportion of total consultations. The variable time was categorised as an 102 
ordinal variable into quarters of the year (Q1, Q2, Q3 and Q4) and included as a fixed effect. 103 
Quarter was codified using two contrasting coding systems: (1) an orthogonal polynomial 104 
method11 to analyse for overall trend (see Appendix: Supplementary Table 2); and (2) a 105 
backward differencing method12 to investigate quarter-by-quarter variation in a backward 106 
pairwise manner (e.g. Q1 2016 compared with Q4 2015). A further model was fitted for canine 107 
and feline HPCIA prescription as a proportion of total AAP. A likelihood ratio test (LRT) 108 
indicated that including practice and premise as random effects in all models provided the best 109 
fit. Statistical significance was defined as P < 0.05 and all analyses were carried out using R 110 
(version 3.2.3).13 111 
Results 112 
A total of 918,333 canine EHRs (from 413,870 dogs) and 352,730 feline EHRs (from 113 
200,541 cats) were obtained from 216 veterinary practices (457 premises) from 1 April 2014 to 114 
31 March 2016. 115 
Consultation and animal level 116 
The percentage of consultations where at least one antimicrobial agent was prescribed 117 
(AAPC) was significantly greater for dogs (18.8%, 95% confidence interval, CI, 18.2-19.4) 118 
than cats (17.5%, 95% CI 16.9-18.1). Systemic AAPC was significantly less frequent in dogs 119 
(12.2%, 95% CI 11.7-12.7) than cats (14.8%, 95% CI 14.2-15.4), representing 64.9% (95% CI 120 
63.8-66.0) and 84.5% (95% CI 83.9-85.2) of total canine and feline AAPC, respectively (paired 121 
t test; P < 0.001). Topical AAPC was significantly more frequent in dogs (7.4% of 122 
                                                          
11 See: http://www.ats.ucla.edu/stat/r/library/contrast_coding.htm#ORTHOGONAL (accessed 11 October 2016). 
12 See: http://www.ats.ucla.edu/stat/r/library/contrast_coding.htm#backward (accessed 11 October 2016). 
13 See: http://www.R-project.org/ (accessed 23 November 2016). 
 consultations, 95% CI 7.2-7.7) than cats (3.2%, 95% CI 3.1-3.3), representing 39.6% (95% CI 123 
38.5-40.6) and 18.3% (95% CI 17.7-19.0) of AAPC, respectively (P < 0.001). Dogs and cats 124 
were co-prescribed systemic and topical antimicrobial agents in 0.87% (95% CI 0.84-0.94) and 125 
0.59% (95% CI 0.54-0.64) of total consultations, respectively. Significant positive correlations 126 
were found between dogs and cats at premise level for total (0.62, 95% CI 0.56-0.67, P < 0.001), 127 
systemic (0.61, 95% CI 0.54-0.66, P < 0.001) and topical (0.21, 95% CI 0.12-0.30, P < 0.001) 128 
AAPC (Fig. 1). 129 
Fig. 2 shows AAPC categorised by quarter. A significant negative linear trend was 130 
observed for canine total and systemic AAPC, and feline total, systemic and topical AAPC (P 131 
< 0.001; see Appendix: Supplementary Table 3). A significant negative trend by quarter was 132 
observed for canine topical AAPC (P < 0.001). Results of quarter-by-quarter comparison 133 
models can be found in Supplementary Table 4 (see Appendix). 134 
Over the 2 year period, at the animal level, 28.4% (95% CI 27.2-29.7) of dogs were 135 
prescribed an antimicrobial agent, compared with 23.3% (95% CI 22.3-24.4) of cats. When 136 
route of administration was considered, 19.6% (95% CI 18.4-20.7) of dogs and 20.0% (18.9-137 
21.0) of cats were prescribed a systemic antimicrobial agent, and 12.9% (95% CI 12.3-13.5) of 138 
dogs and 5.0% (95% CI 4.7-5.2) of cats were prescribed a topical antimicrobial agent. 139 
Total AAPC was 35.5% (95% CI 34.5-36.5) of unhealthy dogs, 35.1% (95% CI 34.1-140 
36.1) of unhealthy cats, 7.4% (95% CI 6.7-8.0) of healthy dogs and 5.5% (95% CI 4.9-6.2) of 141 
healthy cats. Systemic AAPC was more frequent in unhealthy cats (30.5%, 95% CI 29.5-31.5) 142 
than unhealthy dogs (24.1%, 95% CI 23.1-25.0). The MPCs with the highest frequencies of 143 
AAPC were pruritus in dogs (51.0%, 95% CI 49.8-52.2) and trauma in cats (53.5%, 95% CI 144 
52.1-54.8). Antimicrobial agents were prescribed in a significantly greater proportion of dogs 145 
than cats for gastroenteric (P < 0.001), pruritus (P < 0.001), kidney disease (P < 0.001), other 146 
unwell (P = 0.012), vaccination (P < 0.001), other healthy (P = 0.001) and post-operative (P = 147 
 0.003) consultations. Cats were prescribed antimicrobial agents significantly more frequently 148 
than dogs for respiratory (P < 0.001) and trauma (P < 0.001) consultations. Full results are 149 
presented in Tables 1 and 2. 150 
Level of antimicrobial agent prescription 151 
A total of 218,700 canine and 71,089 feline AAPs were made from 215 practices (455 152 
premises) in the UK. 153 
Authorisation - For systemic AAP, 90.0% (95% CI 88.5-91.4) of canine and 92.9% 154 
(95% CI 91.7-94.1) of feline AAPs were species authorised, with 0.6% (95% CI 0.2-0.9) and 155 
5.2% (95% CI 4.0-6.5) authorised in other veterinary species; of these, 8.2% (95% CI 7.0-9.4) 156 
and 1.7% (95% CI 1.4-2.1) were human authorised, 0.9% (95% CI 0.4-1.3) and 0.05% (95% 157 
CI 0.03-0.07) were dual generic and 0.4% (95% CI 0.1-0.6) and 0.04% (95% CI 0.00-0.09) 158 
were expired or of unknown authorisation, respectively. Metronidazole was the most frequently 159 
prescribed human authorised systemic antimicrobial agent in dogs (96.7% of human authorised 160 
systemic AAP, 95% CI 95.3-98.1) and cats (94.2%, 95% CI 92.1-96.3). 161 
Class of antimicrobial agent - Clavulanic acid potentiated amoxicillin was the most 162 
frequently prescribed antimicrobial agent in dogs (28.6% of total AAP, 95% CI 27.4-29.8) and 163 
cefovecin was the most frequently prescribed antimicrobial agent in cats (36.2%, 95% CI 33.9-164 
38.5) (Tables 3, 4 and 5). Fusidic acid was the most frequently prescribed topical antimicrobial 165 
agent in dogs (44.3% of topical AAP, 95% CI 43.1-45.4) and cats (55.1%, 95% CI 53.6-56.6). 166 
Highest priority critically important antimicrobial agents - Canine and feline HPCIA 167 
prescriptions were 5.4% (95% CI 4.6-6.1) and 39.2% (95% CI 36.8-41.7) of total AAPs 168 
respectively. On consideration of temporal trend, for canine HPCIA prescription, a significant 169 
positive cubic trend was noted (P < 0.001). Similarly, in cats, a significant positive linear trend 170 
was found (P < 0.001) (see Appendix: Supplementary Tables 3 and 4). The most frequently 171 
 prescribed HPCIAs in dogs were fluoroquinolones and in cats was cefovecin, a third generation 172 
cephalosporin (Fig. 3). 173 
Main presenting complaint - Total canine and feline AAPs summarised by MPCs are 174 
shown in Supplementary Tables 5 and 6 (see Appendix). Clavulanic acid potentiated 175 
amoxicillin was the most commonly prescribed antimicrobial agent in dogs for respiratory 176 
conditions, trauma, tumours and kidney disease, as well as other unwell, post-operative and 177 
other healthy MPCs. In cats, cefovecin was the most commonly prescribed antimicrobial agent 178 
for respiratory conditions, pruritus, trauma, tumours and kidney disease, as well as other unwell, 179 
post-operative and other healthy MPCs. 180 
Discussion 181 
In this study, EHRs were used to describe AAP in a large population of companion 182 
animal veterinary premises. Quantitative differences in AAP were found between dogs and cats, 183 
and according to MPC. AAPC decreased significantly over the course of the study in this 184 
population of animals. 185 
Broadly similar levels of total AAP were found in dogs and cats. However, when route 186 
of administration was considered, dogs were significantly more likely to be prescribed topical 187 
antimicrobial agents than cats, whereas cats were significantly more likely to be prescribed 188 
systemic antimicrobial agents than dogs. Such differences may reflect an increased prevalence 189 
of pruritus (and other dermatological diseases) in dogs compared to cats (Sánchez-Vizcaíno et 190 
al., 2016). They may also reflect the challenge of giving oral and topical medication to cats 191 
when compared to injectable antimicrobial agents (Burke et al., 2016). 192 
Using data derived from EHRs, it was not possible to determine whether individual 193 
prescriptions were appropriate, nor whether the overall frequency of AAP in this population 194 
was appropriate. However, there was a significant reduction in canine and feline AAP within 195 
this population over the 2 years of the study. Whether this reflects the success of awareness 196 
 campaigns is not known.14,15 It is possible that changes in AAP might reflect changes in other 197 
aspects of veterinary activity, such as vaccination. Furthermore, previous human AAP 198 
surveillance has noted short-term temporal variability that is not necessarily reflective of longer 199 
term patterns.16 As a consequence, there is a need to for ongoing monitoring of AAP. 200 
Buckland et al. (2016) found that 25.2% of dogs and 20.6% of cats in the UK received 201 
systemic antimicrobial agents from 2012 to 2014. Whilst our results (2014-2016) were lower 202 
for dogs (19.6%), they were similar for cats (20.0%). In a smaller study conducted in the UK 203 
in 2010 (Radford et al., 2011), the proportion of consultations involving unhealthy animals 204 
where systemic antimicrobial agents were prescribed was 35.1% for dogs and 48.5% for cats. 205 
In our study, these values were lower (unhealthy dogs 24.1%, unhealthy cats 30.5%). It is 206 
unclear whether differences between these studies reflect a reduction in frequency of 207 
prescription of systemic antimicrobial agents, or are related to population differences or 208 
methods used to identify AAP. 209 
Considerable variation in AAPs according to premise was identified in our study, as 210 
well as in the previous study by Radford et al. (2011). Premises that prescribed antimicrobial 211 
agents more frequently to dogs also tended to prescribe more frequently to cats. Such a 212 
correlation may be explained by geographical variation in risk (perceived or actual), either for 213 
AMR or for bacterial infections capable of infecting both species. Other complex factors, 214 
extending beyond the risk of antimicrobial agent responsive disease, can influence AAP 215 
decisions, such as clinical experience, perceived owner and/or pet compliance and practice 216 
policy (Hughes et al., 2012; Mateus et al., 2014). 217 
It is not surprising that certain MPCs were more commonly associated with AAP, 218 
suggesting that practitioners believe that the risk of infection responsive to antimicrobial agents 219 
                                                          
14 See: http://www.fecava.org/content/guidelines-policies (accessed 15 July 2016). 
15 See: http://www.bsava.com/Resources/PROTECT.aspx (accessed 4 October 2016). 
16 See: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-consumption-europe-esac-net-2012.pdf 
(accessed 26 January 2017). 
 is higher in certain MPCs. Pruritus in dogs is frequently associated with bacterial pyoderma 220 
(Summers et al., 2014) and was associated with the most frequent use of topical antimicrobial 221 
agents in our study. However, acute respiratory disease in cats is generally considered to have 222 
a viral origin, although primary bacterial disease has been described and secondary bacterial 223 
infections can increase the severity of disease (Jacobs et al., 1993). Prescription of antimicrobial 224 
agents in feline trauma may reflect a high frequency of cat bite abscesses associated with this 225 
MPC (Radford et al., 2011; O’Neill et al., 2014b). 226 
In dogs, clavulanic acid potentiated amoxicillin was the most frequently prescribed 227 
antimicrobial agent, as found in previous studies (Mateus et al., 2011; Radford et al., 2011; 228 
Buckland et al., 2016). In our study and that of Buckland et al. (2016), cefovecin was the most 229 
frequently prescribed antimicrobial agent in cats, in contrast to previous studies, where 230 
amoxicillin and clavulanic acid potentiated amoxicillin were more frequently prescribed 231 
(Mateus et al., 2011; Radford et al., 2011). This suggests that there has been a recent shift in 232 
choice of antimicrobial agents for cats. Prescription of cefovecin was common for MPCs 233 
associated with authorised indications for use, such as pruritus and kidney disease17 (Burke et 234 
al., 2016). However, cefovecin was also prescribed frequently in MPCs, such as respiratory and 235 
gastroenteric disease in cats, where there was no apparent indication for prescription by the 236 
datasheet1 or practice prescribing policy.18,19 It is also possible that relying on MPCs as declared 237 
by veterinary practitioners might fail to include other clinical conditions found during the same 238 
consultation. Collection and analysis of clinical free text presents an opportunity to characterise 239 
each consultation based on clinical signs and duration, which would provide further information 240 
to support the rationale for any given prescription (Burke et al., 2016). 241 
                                                          
17 See: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/veterinary/000098/WC500062067.pdf (accessed 12 December 2016). 
18 See: http://www.fecava.org/content/guidelines-policies (accessed 15 July 2016). 
19 See: http://www.bsava.com/Resources/PROTECT.aspx (accessed 4 October 2016). 
 Although cefovecin is not authorised for human use, it is a third generation 242 
cephalosporin and is classified as an HPCIA.20,21 Relevant product information sheets state that 243 
cefovecin should be reserved for clinical conditions which have responded poorly, or are 244 
expected to respond poorly, to other classes of antimicrobial agents.22 In our study, it was not 245 
possible to determine to what extent the use of cefovecin is in compliance with these 246 
recommendations. A recent study showed that veterinary surgeons prescribing cefovecin rarely 247 
justified its use within the clinical narrative (Burke et al., 2016). Relative ease of administration 248 
and duration of action, together aiding compliance, may be important motivating factors for the 249 
use of cefovecin in veterinary practice. We noted considerable variation in prescription of 250 
cefovecin between premises, suggesting that there are differences in cat populations, 251 
presentations or justification for veterinary prescription. We further observed a slight increase 252 
in overall HPCIA prescription in dogs and cats throughout the study, and that many of the most 253 
commonly prescribed antimicrobial agents in both species are considered to be critically 254 
important.23 255 
Whilst such large volumes of data provide new insights into AAP, the nature of these 256 
data have their own inherent limitations. Quantification of AAP relies on practitioners charging 257 
for antimicrobial agents through their practice management software, which means that any 258 
antimicrobial agents not charged for will be missed. The SAVSNET population of practices is 259 
recruited on the basis of convenience and so cannot necessarily be considered to be 260 
representative of the wider UK population. In order to fully place findings in context, there is a 261 
need for in depth analysis of the animal populations monitored. The use of the MPC function 262 
                                                          
20 See: http://www.who.int/foodsafety/publications/antimicrobials-fourth/en/ (accessed 13 February 2017). 
21 See: http://www.noah.co.uk/wp-content/uploads/2016/12/NOAH-briefing-on-CIAs-07122016.pdf (accessed 
14 February 2017). 
22 See: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/veterinary/000098/WC500062067.pdf (accessed 12 December 2016). 
23 See: http://www.who.int/foodsafety/publications/antimicrobials-fourth/en/ (accessed 13 February 2017). 
 allows all consultations to be coded in real time; variations in individual interpretation of the 263 
MPC case definition are possible. 264 
Conclusions 265 
 AAP frequency decreased from 2014 to 2016 in this population of dogs and cats in the 266 
UK. Additionally, some MPCs were more likely to be associated with AAP than others, both 267 
within and between the two species. There is considerable variability in AAP amongst different 268 
premises and there is a need to understand factors that influence AAP at the individual animal, 269 
owner and premise level, particularly for HPCIAs. To aid responsible use, SAVSNET provides 270 
a mechanism for participating practices to benchmark their prescription against anonymised 271 
peers via an online portal. This and other studies are now providing the valuable tools and data 272 
that the profession needs to ensure antimicrobial agents are used responsibly. 273 
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 Table 1 359 
Canine antimicrobial agent prescription percentage (total, systemic and topical) by practitioner badged main 360 
presenting complaint calculated from total number of consultations for each category in a network of United 361 
Kingdom small animal veterinary premises. 362 
Main presenting 
complaint 
Dog 
Number (%) of 
EHRs a 
Total Systemic Topical 
% 95% CI b % CI b % CI b 
Pruritus 62,655 (6.8) 51.0 49.8-52.2 25.5 24.2-26.9 30.0 29.0-31.0 
Respiratory 14,359 (1.6) 42.2 40.5-44.0 40.4 38.7-42.2 2.7 2.2-3.2 
Gastroenteric 38,954 (4.2) 39.4 37.0-41.7 38.2 35.8-40.6 1.7 1.2-2.2 
Trauma 58,033 (6.3) 26.7 25.5-27.9 21.3 20.3-22.4 6.2 5.8-6.6 
Kidney disease 2607 (0.28) 29.1 26.6-31.7 26.8 24.3-29.3 3.0 2.2-3.7 
Tumour 20,938 (2.3) 22.0 21.1-23.0 17.5 16.7-18.3 5.4 5.0-5.8 
Other unwell 156,197 (17.0) 32.8 31.8-33.8 20.3 19.5-21.2 13.9 13.4-14.5 
Post-operative 98,753 (10.8) 13.0 12.2-13.8 9.9 9.3-10.5 3.5 3.1-3.8 
Vaccination 277,246 (30.2) 4.3 3.9-4.7 1.4 1.1-1.7 3.0 2.8-3.2 
Other healthy 188,582 (20.6) 11.8 10.7-13.0 7.0 6.1-7.8 5.3 4.8-5.9 
 363 
a Number (%) of electronic health records (EHRs). Relative occurrence of badged consultations as a frequency 364 
and as a percentage of total consultations. 365 
Table 2 366 
Feline antimicrobial agent prescription percentage (total, systemic and topical) by practitioner badged main 367 
presenting complaint calculated from total number of consultations for each category in a network of United 368 
Kingdom small animal veterinary premises. 369 
Main presenting 
complaint 
Cat 
Number (%) of 
EHRs a 
Total Systemic Topical 
% 95% CI b % 95% CI b % 95% CI b 
Pruritus 13,749 (3.9) 33.5 31.9-35.2 24.9 23.3-26.6 10.3 9.5-11.1 
Respiratory 7681 (2.2) 52.0 49.8-54.3 59.9 47.6-52.2 5.3 4.6-5.9 
Gastroenteric 11,206 (3.2) 29.8 27.4-31.8 28.9 26.7-31.1 1.0 0.7-1.4 
Trauma 22,796 (6.5) 53.5 52.1-54.8 50.1 48.8-51.4 4.3 4.0-4.7 
Kidney disease 4009 (1.1) 19.6 17.9-21.3 18.9 17.2-20.6 0.7 0.5-1.0 
Tumour 5330 (1.5) 21.3 19.8-22.7 19.8 18.3-21.3 1.7 1.4-2.0 
Other unwell 72,189 (20.5) 30.5 29.5-31.6 24.9 23.9-26.0 6.5 6.3-6.8 
Post-operative 32,136 (9.1) 11.1 10.0-11.9 9.6 8.7-10.6 1.7 1.4-2.0 
Vaccination 115,394 (32.6) 2.5 2.2-2.8 1.4 1.2-1.6 1.2 1.1-1.3 
Other healthy 68,236 (19.4) 10.5 9.1-11.9 8.4 7.1-9.6 2.4 2.1-2.7 
 370 
a Number (%) of electronic health records (EHRs). Relative occurrence of badged consultations as a frequency 371 
and as a percentage of total consultations. 372 
 b 95% Confidence interval.373 
 Table 3 374 
Percentage breakdown of canine antimicrobial agent prescriptions by antimicrobial agent class prescribed for 375 
total, systemic and topical prescriptions from a network of United Kingdom small animal veterinary premises. 376 
 377 
Antimicrobial agent class 
Total Systemic Topical 
% 95% CI a % 95% CI a % 95% CI a 
Aminoglycoside 12.0 11.4-12.6 0.1 0.0-0.2 29.1 28.0-30.2 
Amphenicol 1.9 1.6-2.1 0.0  < 0.00 4.5 3.9-5.2 
Other antimicrobial agent b 7.2 6.6-7.8 0.0  < 0.00 17.4 16.1-18.8 
β-lactam 43.6 42.3-44.8 73.8 72.2-75.4 0.1 0.0-0.2 
Fluoroquinolone 4.4 3.6-5.1 4.1 3.1-5.2 4.6 4.0-5.2 
Fusidic acid 18.2 17.4-19.0 0.0  < 0.00 44.3 43.1-45.4 
Lincosamide 4.7 4.2-5.2 7.9 7.0-8.8 0.0  < 0.00 
Macrolide 0.2 0.0-0.3 0.3 0.0-0.6 0.0  < 0.00 
Nitroimidazole 4.7 4.0-5.4 8.0 6.7-9.2 0.0  < 0.00 
Nitroimidazole-macrolide 0.8 0.5-1.0 1.3 0.8-1.7 0.0  < 0.00 
Rifamycin 0.0  < 0.00 0.0  < 0.00 0.0  < 0.00 
Sulphonamide 1.5 1.1-1.9 2.5 1.9-3.2 0.0  < 0.00 
Tetracycline 1.2 1.0-1.3 2.0 1.7-2.2 0.0 0.00-0.01 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
a 95% Confidence interval. 394 
b Consists of polymyxin b sulphate; mupirocin; novobiocin; thymol and bronopol.395 
 Table 4 396 
Percentage breakdown of feline antimicrobial agent prescriptions by antimicrobial agent class prescribed for 397 
total, systemic and topical prescriptions from a network of United Kingdom small animal veterinary premises. 398 
 399 
Class of antimicrobial agent 
Total Systemic Topical 
% 95% CI a % 95% CI a % 95% CI a 
Aminoglycoside 4.5 4.2-4.8 0.2 0.1-0.3 22.1 20.7-23.6 
Amphenicol 1.3 1.1-1.5 0.0  < 0.00 6.5 5.6-7.4 
Other antimicrobial agent b 2.7 2.4-2.9 0.0  < 0.00 13.5 12.4-14.6 
β-lactam 70.8 69.3-72.3 87.9 86.1-89.7 0.3 0.0-0.6 
Fluoroquinolone 3.0 1.7-4.3 3.1 1.6-4.7 2.5 2.0-3.0 
Fusidic acid 10.8 10.2-11.3 0.0  < 0.00 55.1 53.6-56.6 
Lincosamide 4.1 3.5-4.7 5.2 4.4-5.9 0.0  < 0.00 
Macrolide 0.05 0.01-0.09 0.07 0.01-0.12 0.0  < 0.00 
Nitroimidazole 1.3 1.1-1.6 1.6 1.3-2.0 0.0  < 0.00 
Nitroimidazole-macrolide 0.4 0.2-0.5 0.5 0.3-0.7 0.0  < 0.00 
Rifamycin 0.0  < 0.00 0.0 c  < 0.00 0.0  < 0.00 
Sulphonamide 0.05 0.03-0.07 0.06 0.03-0.09 0.0  < 0.00 
Tetracycline 1.1 1.0-1.3 1.4 1.2-1.6 0.0  < 0.00 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
a 95% Confidence interval. 418 
b Polymyxin b sulphate, mupirocin, novobiocin, thymol and bronopol. 419 
c One recorded prescription of rifampicin for systemic administration (authorised for oral administration).  420 
 Table 5 421 
Percentage breakdown of β-lactam antimicrobial agent prescription by species and β-lactam sub-categories as a 422 
percentage of total and systemic antimicrobial agent prescriptions from a network of small animal veterinary 423 
premises in the United Kingdom. 424 
 425 
 
Class of antimicrobial agent 
Total prescription Systemic prescription 
Dog Cat Dog Cat 
% 95% CI a % CI a % CI a % CI a 
Amoxicillin 5.3 4.1-6.5 12.5 10.0-15.0 9.0 7.1-10.9 15.3 12.2-18.3 
Other β-lactams b 0.4 0.0-0.8 0.07 0.01-0.13 0.5 0.0-1.3 0.02 0.00-0.05 
First generation cephalosporin 8.4 7.8-9.0 0.4 0.3-0.5 14.2 13.2-15.3 0.5 0.4-0.6 
Second generation cephalosporin 0.04 0.01-0.07 0.01 0.00-0.02 0.07 0.02-0.12 0.02 0.00-0.03 
Third generation cephalosporin 0.9 0.7-1.0 36.2 33.9-38.5 1.5 1.3-1.8 45.1 42.1-48.2 
Clavulanic acid potentiated amoxicillin 28.6 27.4-29.8 21.6 19.6-23.6 48.5 46.0-50.9 26.9 24.5-29.3 
Penicillin 0.03 0.01-0.05 0.03 0.01-0.05 0.04 0.01-0.07 0.04 0.01-0.06 
Total 43.6  70.8  73.8  87.9  
 426 
a 95% confidence interval. 427 
b Ampicillin and cloxacillin.428 
 Figure legends 
 
Fig. 1. Comparison of canine and feline antimicrobial agent prescription as a percentage of total 
consultations (AAPC) by premises (n = 457) split by (a) total, (b) systemic and (c) topical 
antimicrobial agent prescription. 
 
Fig. 2. Comparison of (a) canine (n = 918,333 electronic health records) and (b) feline (n = 
352,730) total, systemic and topical antimicrobial agent prescription as a percentage of total 
consultations (95% confidence interval) by quarter (Q2 2014-Q1 2016). 
 
Fig. 3. Comparison of (a) canine and (b) feline highest priority ‘critically important 
antimicrobial agent’ (HPCIA) prescription as a percentage of total antimicrobial agent 
prescriptions (95% confidence interval) by quarter (Q2 2014-Q1 2016). 
  
  
b 95% Confidence interval.
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